Skip to content

Nektar Therapeutics

US · NKTR #3017 by market cap Listed 1970
30.20 -2.34 -7.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership rose 5.0 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
110.35% +5.05pp
Institutions
279 +6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund53.94%
Hedge Fund43.03%
Public Company5.32%
VC/PE Fund4.15%
Private Company2.60%
Sovereign Wealth Fund0.63%
Government Pension Fund0.41%
Individual/Insider0.37%
Insurance Company0.24%

Top holders as of 2026-09-30

FMR 15.00% · 5.12M sh
Two Seas Capital LP 9.80% · 3.35M sh
BlackRock 8.41% · 2.87M sh
BVF Partners L.P. 7.00% · 2.39M sh
State Street Global Advisors 5.19% · 1.77M sh
Vanguard Capital Management, LLC 4.40% · 1.50M sh
Two Sigma Investments, LP 3.52% · 1.20M sh
Vestal Point Capital, LP 2.93% · 1.00M sh
Geode Capital Management, LLC 2.61% · 891.93K sh
Morgan Stanley 2.43% · 830.21K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 27 buys · 23 sells

NameRoleStake
Howard Robin Chief Executive Officer 0.16%
R. Greer Independent Director 0.06%
Roy Whitfield Lead Independent Director 0.06%
Robert Chess Independent Chairperson 0.05%
Jonathan Zalevsky Senior VP and Chief Research & Development Officer 0.03%
Jeffrey Ajer Independent Director 0.01%
Diana Brainard Independent Director 0.01%
Mark Wilson Former Chief Legal Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-22 Robert Chess Independent Chairperson Other Acquisition +2,000 --
2026-09-22 Robert Chess Independent Chairperson Other Derivative Acquisition +4,000 $57.66
2026-09-22 R. Greer Independent Director Other Acquisition +2,000 --
2026-09-22 R. Greer Independent Director Other Derivative Acquisition +4,000 $57.66
2026-09-22 Roy Whitfield Lead Independent Director Other Acquisition +2,000 --
2026-09-22 Roy Whitfield Lead Independent Director Other Derivative Acquisition +4,000 $57.66
2026-09-22 Jeffrey Ajer Independent Director Other Acquisition +2,000 --
2026-09-22 Jeffrey Ajer Independent Director Other Derivative Acquisition +4,000 $57.66
2026-09-22 Diana Brainard Independent Director Other Acquisition +2,000 --
2026-09-22 Diana Brainard Independent Director Other Derivative Acquisition +4,000 $57.66
2026-08-17 Howard Robin Chief Executive Officer Open Market Disposition -418 $71.98
2026-08-17 Jonathan Zalevsky Senior VP and Chief Research & Development Officer Open Market Disposition -186 $71.98
2026-07-23 Howard Robin Chief Executive Officer Other Derivative Acquisition +57,200 $15.15
2026-07-23 Jonathan Zalevsky Senior VP and Chief Research & Development Officer Other Derivative Acquisition +16,500 $15.15
2026-06-29 Jonathan Zalevsky Senior VP and Chief Research & Development Officer Automatic Disposition -5,681 $70.00
2026-06-16 Howard Robin Chief Executive Officer Automatic Disposition -20,000 $59.97–61.65
2026-06-16 Howard Robin Chief Executive Officer Intent to Sell (Form 144) -10,000 $60.27
2026-06-15 Howard Robin Chief Executive Officer Intent to Sell (Form 144) -10,000 $60.96
2026-06-14 Jonathan Zalevsky Senior VP and Chief Research & Development Officer Automatic Disposition -5,538 $60.71
2026-05-18 Howard Robin Chief Executive Officer Open Market Disposition -444 $65.51

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:35 · For reference only, not investment advice and not tailored to your situation.

Nektar Therapeutics discussion 0 comments

Add a comment